- Home
- JAGX vs XXII Comparison
JAGX vs XXII Comparison
Compare JAGX & XXII Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JAGX
- XXII
- Stock Information
- Founded
- JAGX 2013
- XXII 1998
- Country
- JAGX United States
- XXII United States
- Employees
- JAGX N/A
- XXII N/A
- Industry
- JAGX Biotechnology: Pharmaceutical Preparations
- XXII Medicinal Chemicals and Botanical Products
- Sector
- JAGX Health Care
- XXII Health Care
- Exchange
- JAGX Nasdaq
- XXII Nasdaq
- Market Cap
- JAGX 3.1M
- XXII 2.8M
- IPO Year
- JAGX N/A
- XXII N/A
- Fundamental
- Price
- JAGX $4.67
- XXII $1.30
- Analyst Decision
- JAGX
- XXII
- Analyst Count
- JAGX 0
- XXII 0
- Target Price
- JAGX N/A
- XXII N/A
- AVG Volume (30 Days)
- JAGX 39.3K
- XXII 52.8K
- Earning Date
- JAGX 03-31-2025
- XXII 03-20-2025
- Dividend Yield
- JAGX N/A
- XXII N/A
- EPS Growth
- JAGX N/A
- XXII N/A
- EPS
- JAGX N/A
- XXII N/A
- Revenue
- JAGX $11,689,000.00
- XXII $24,382,000.00
- Revenue This Year
- JAGX $18.18
- XXII $45.16
- Revenue Next Year
- JAGX $40.06
- XXII $48.70
- P/E Ratio
- JAGX N/A
- XXII N/A
- Revenue Growth
- JAGX 19.75
- XXII N/A
- 52 Week Low
- JAGX $4.40
- XXII $1.24
- 52 Week High
- JAGX $540.00
- XXII $581.85
- Technical
- Relative Strength Index (RSI)
- JAGX 20.41
- XXII 27.85
- Support Level
- JAGX $4.41
- XXII $1.32
- Resistance Level
- JAGX $4.97
- XXII $1.51
- Average True Range (ATR)
- JAGX 0.88
- XXII 0.15
- MACD
- JAGX 0.09
- XXII 0.05
- Stochastic Oscillator
- JAGX 3.35
- XXII 8.45
About JAGX Jaguar Health Inc.
Jaguar Health Inc is a commercial-stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. Its product Mytesi is a novel, first-in-class anti-secretory agent which has a basic normalizing effect locally on the gut, and this mechanism of action has the potential to benefit multiple disorders. It has two reportable segments namely human health and animal health. The company generates the majority of its revenue from the Human Health segment.
About XXII 22nd Century Group Inc.
22nd Century Group Inc is a United States-based biotechnology company focused on utilizing alkaloid plant technologies to improve health and wellness with reduced nicotine tobacco, and hemp/cannabis. It has one operating segment; The tobacco segment is engaged in commercializing its proprietary VLNC tobacco plants and cigarette products, which contain nicotine than conventional tobacco and cigarettes, and research cigarettes sold under the brand name SPECTRUM. It derives a majority of its revenue from the tobacco segment.